MENU
Articles by #hashtag

pharmaceuticalindustry

51 hits

Richter Revenue Growth in Line with Expectations

D&T
Aug 6, 2025

The Hungarian pharma company Gedeon Richter Plc.'s consolidated sales revenue for the first half of the year was HUF 465.5 billion, 10.9% higher than a year earlier, the company announced on the Budapest Stock Exchange (BÉT) website on Wednesday. Net profit for the first half of 2025 was HUF 120 billion, which is 13% lower […]

Pioneering Access for Patients

D&T
Aug 3, 2025

Switzerland-based pharmaceutical company Sandoz came to be an independent company in October 2023. For 20 years prior to that, it was the generic businesses division of Novartis. Now, Sandoz is a global leader in generic pharmaceuticals and biosimilars with the focus on bringing high quality medicines early to patients at affordable cost. The local subsidiary, […]

Leading with Innovation, Ethics and Impact

D&T
Jul 31, 2025

Hungary’s leading innovative pharmaceutical company, Novartis has been present in this country since the early nineties. The head of the local subsidiary, Novartis Hungary Ltd., Colette Matz tells Diplomacy&Trade about the company’s activities on the Hungarian market with special regard to the company’s contribution to Hungarian healthcare. The General Manager states that Novartis is proud […]

Major Egis Investment in Körmend

D&T
Jul 28, 2025

French-owned Hungarian pharmaceutical company Egis Gyógyszergyár Plc. is set to implement another large-scale investment to boost efficiency and capacity at its base in Körmend, the Hungarian Investment Promotion Agency (HIPA) reports. The EUR 37.5 million investment include the modernisation of the a tableting plant and the galenic plant, and the extension of the storage facility […]

Richter Yields to Government Price Restriction Demand

D&T
Jun 11, 2025

The Hungarian pharmaceutical company Gedeon Richter Plc. has announced on the website of the Budapest Stock Exchange that “understanding and supporting the Hungarian government's efforts to reduce the burden on patients, voluntarily restricts the price of its non-prescription product Panangin®, a magnesium and potassium dietary supplement and complementary treatment for chronic heart disease and cardiac […]

Goodwill Pharma: Significantly Higher Sales Revenue, Profits

D&T
May 28, 2025

Goodwill Pharma Plc. significantly increased its net sales revenue last year by 27% compared to the previous year, with the company's after-tax profit amounting to HUF 2.155 billion, compared to HUF 1.502 billion a year earlier, according to the consolidated report published by the Szeged-based pharmaceutical company on the BSE website. According to the balance […]

New Biotech Player Joins Hungary’s Pharma Landscape

D&T
Apr 25, 2025

Hungary continues to strengthen its position in the pharmaceutical industry as Singapore-based Hongene Biotech has announced the establishment of its first European manufacturing facility in Gödöllő, just east of Budapest. The nearly EUR 94 million greenfield investment will create 150 new jobs and contribute significantly to Hungary’s export performance, according to the Hungarian Investment Promotion […]

Two Richter Products Recommended for Marketing

D&T
Apr 25, 2025

Budapest-based pharmaceutical company Gedeon Richter Plc. has received positive opinion from CHMP for marketing authorization for Junod and Yaxwer, its biosimilar denosumab products for bone disease and osteoporosis. Budapest-based pharmaceutical company Gedeon Richter Plc. has announced on the website of the Budapest Stock Exchange that it received a positive opinion from the Committee for Medicinal […]

Science at the Patients' Service

D&T
Apr 16, 2025

At the Sanofi Pharmaceutical Innovation Center, the biopharmaceutical company is now presenting its global immunology strategy, highlighting the role of innovative medicines and vaccines in the future of medicine. First unveiled at the 2024 Olympic and Paralympic Games in Paris, the Sanofi Science Lab will now be the only one in Central Europe to be […]

Richter Reports Another Record Year

D&T
Feb 28, 2025

Budapest-based pharmaceutical giant Gedeon Richter Plc. announced its Q4/FY 2024 financial results at the website of the Budapest Stock Exchange by stating that 2024 was an active year with business development across all segments, aimed at providing access to health by bringing solutions to unmet needs and by offering affordable medicines to a wide range […]

Goodwill Pharma Expands Production, Warehouse Capacity

D&T
Feb 14, 2025

Hungary's Goodwill Pharma Plc. has expanded its warehouse capacity, built a research and development and innovation laboratory, a new head office and a pharmaceutical manufacturing plant in Szeged, Hungary, the almost HUF 5 billion investment was handed over on Thursday. Ferenc Jójárt, CEO of the Szeged-based company, said at the ceremony that Goodwill Pharma is […]

Richter Announces Positive Topline Results for RGB-19

D&T
Jan 15, 2025

Gedeon Richter has announced positive topline results from Phase I and Phase III clinical studies for its proposed biosimilar to RoActemra® tocilizumab that has the development code 'RGB-19'. The Hungarian pharmaceutical firm points out in a statement on the webiste of the Budapest Stock Exchange that Phase I clinical study evaluated the equivalence of pharmacokinetics […]

Egis Expands Portfolio with Well-Known Product Line

D&T
Jan 13, 2025

Egis Pharmaceuticals Plc. has acquired one of Teva Pharmaceuticals Plc.'s well-known product family for skin application, following the approval of the competition authority, the pharmaceutical manufacturer informed MTI on Monday. According to the statement, the takeover of the distribution and promotion of the product line began on December 17, 2024, and the parties sought to […]

FDA Submission Acceptance for Richter Products

D&T
Dec 12, 2024

Gedeon Richter Plc. and Hikma Pharmaceuticals Plc. has announced that the U.S. Food and Drug Administration (FDA) had accepted for review the Biologics License Applications (BLA) for RGB-14, a Denosumab biosimilar candidate comprising two biosimilar products referencing Prolia® and Xgeva®, a human monoclonal antibody for the treatment of osteoporosis and fractures due to bone metastasis, […]

Ceva-Phylaxia to Build New Vaccine Factory in Monor

D&T
Nov 14, 2024

As part of its commitment to expanding its presence in Hungary, global animal vaccine producer Ceva-Phylaxia has announced an EUR 75 million investment, establishing a state-of-the-art unit in Monor dedicated to manufacturing inactivated, multicomponent vaccines, the Hungarian Investment Promotion Agency (HIPA) reports. Following the official groundbreaking ceremony for the 7,000-square-meter facility, production is expected to […]

© Copyright 2026 Duax Kft. –  All rights reserved.
sun
Diplomacy & Trade
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.